16 September 2026 editorial review · Item
GNTI-122 engineered Tregs (POLARIS): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: GNTI-122 POLARIS has HLA restriction, n=16, a rapamycin-combination cohort and sponsor-confirmed first dosing. Treg persistence and preservation remain intended outcomes.
- Registry NCT06919354: RECRUITING; updated 2026-08-10; enrollment 16 (ESTIMATED); primary completion 2028-02 (ESTIMATED); results not posted in retrieved record.
- Programme/sponsor/conference source boundary: GentiBio — GNTI-122 for new-onset type 1 diabetes (manufacturer); GentiBio announces first participant dosed in POLARIS phase 1 clinical trial of GNTI-122 (manufacturer).